



Diesse Diagnostica Senese S.p.A.

[www.diesse.it](http://www.diesse.it)



## PRESS RELEASE

### DIESSE AUTOMATES THE SARS-CoV-2 KIT IN SINGLE-TEST FORMAT ON THE CHORUS INSTRUMENT

Siena, June 15<sup>th</sup> 2020 - DIESSE Diagnostica Senese is proud to announce, as part of its commitment to the fight against the COVID-19 pandemic, the release today onto the market of patented and CE-marked IVD serological tests Chorus SARS-CoV-2 IgG and IgM, the IgA class will be launched by the end of the month of June.

In addition to the Enzywell serological tests, released in April, single-test format kits are now available, enabling a deeper automation on the automated immunometric analyzers of the Chorus family.

"We will be able to make our SARS-CoV-2 tests on native inactivated virus available in highly automated single-test format, on the over 3000 chorus instruments installed in laboratories all over the world, - says Massimiliano Boggetti, CEO of Diesse - now that the epidemic curve is decreasing and that the need for daily productivity is diminishing. Our Chorus diagnostic kits have a 100% correlation with the Enzywell tests already manufactured by our Company, thus increasing the range of DIESSE available kits against this terrible pandemic."



To ensure a more accurate recognition of the patient's antibodies, DIESSE developed also these serological tests with the native antigen, in order to achieve high sensitivity and specificity in the diagnosis and to make sure that the proteins of the virus (cultivated in BSL3 high-containment biological laboratories) maintain their natural conformation.

The kits have been developed to detect the three types of IgA, IgG and IgM antibodies; especially IgA make the difference on this type of test, because as per scientific literature, the respiratory viruses, including the coronavirus, trigger immune defense at the early stage in the mucous membranes and later at a systematic level. At the mucous membrane level, the immune system produces IgA at the early stages and their diagnosis makes it possible to trace the many asymptomatic cases or those who are in the initial stage of infection.

Enzywell SARS-CoV-2 and Chorus SARS-CoV-2 serological tests are therefore an essential tool to monitor the evolution of COVID patients and help clinicians better understand how our body reacts to infection.

Chorus is a multiparametric system for immunometric assay using single test ready to use devices, easily adapting to the needs of each clinical testing lab, from the largest to the smallest.



**Diesse Diagnostica Senese S.p.A.** is an Italian Company with integrated and entirely in-house production of in vitro diagnostic systems with its headquarters in Siena. Since its foundation in 1980, the company has developed, produced and marketed innovative diagnostic systems mainly in the field of immunodiagnosics and automatic measurement of ESR. The Company has a global presence in over 100 countries, three production sites and a research center where the design and implementation of tests and new automated diagnostic detection tools meet Italian design and cutting-edge technology, making Diesse synonymous with "Diagnostics Evolution".

For further information:

Tatiana Zoppi – Diesse Diagnostica Senese  
Tel.+39 348 3337827 – [tatianazoppi@diesse.it](mailto:tatianazoppi@diesse.it)